Sol-Gel Technologies Ltd.

SLGL

Healthcare Biotechnology

Sol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024.

Revenue
−96.6%
EPS
−127.1%
Free cash flow
−8.76%

Quarter to June 2026, against a year earlier

61.01 2.00 −3.17%
Market cap
$199.8M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
6/9
Net debt / EBITDA
3.2×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
4.28 6.06 12.17 135.10
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
135.58 364.60 697.97 (29.34)
P/B ratio
3.12 5.15 4.37 5.04
EV/Sales
6.63 8.19 12.85 144.80
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(4.29) (7.70) (11.51) (12.22)
Current Ratio
5.15 4.37 8.84 10.37
Net Debt/EBITDA
3.31 7.04 13.70 11.52
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(11.18%) (5.29%) (0.43%) (7.61%)
Free Cash Flow Yield
(36.06%) (17.55%) (9.17%) (8.77%)
Free Cash Flow per Share
0.00 0.12 0.00 (2.53)
Book value per Share
9.34 8.19 18.12 14.70
Free Cash Flow
— 0.33 — (8.29)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates